- We will send in 10–14 business days.
/images/books/13504261/9786203607000.jpg)
- Author: Hayette Sénia Bensaber
- Publisher: Our Knowledge Publishing
- ISBN-10: 6203607002
- ISBN-13: 9786203607000
- Format: 15.2 x 22.9 x 0.4 cm, softcover
- Language: English
- SAVE -10% with code: EXTRA
Reviews
Description
RESUMET-DM1 is the first of an experimental new cancer drug known as an antibody-drug conjugate. It demonstrates an improvement in progression-free survival over standard therapy in HER2-positive metastatic breast cancer. It combines two existing cancer drugs in order to deliver both drugs specifically to cancer cells: Trastuzumab, a monoclonal antibody to target cells that overproduce the HER2 protein; and, T-DM1 is a chemotherapeutic substance.This is the first ever presentation of an anti-HER2 antibody-drug conjugate used as a primary treatment for patients with advanced breast cancer," said Professor Perez. "We are encouraged by the results. The study explained that T-DM1 has very good anti-tumor activity as well as much lower toxicity when evaluated side-by-side to the older "standard". T-DM1 has displayed promising activity in preclinical studies.
EXTRA 10 % discount with code: EXTRA
The promotion ends in 12d.16:39:30
The discount code is valid when purchasing from 10 €. Discounts do not stack.
- Author: Hayette Sénia Bensaber
- Publisher: Our Knowledge Publishing
- ISBN-10: 6203607002
- ISBN-13: 9786203607000
- Format: 15.2 x 22.9 x 0.4 cm, softcover
- Language: English English
RESUMET-DM1 is the first of an experimental new cancer drug known as an antibody-drug conjugate. It demonstrates an improvement in progression-free survival over standard therapy in HER2-positive metastatic breast cancer. It combines two existing cancer drugs in order to deliver both drugs specifically to cancer cells: Trastuzumab, a monoclonal antibody to target cells that overproduce the HER2 protein; and, T-DM1 is a chemotherapeutic substance.This is the first ever presentation of an anti-HER2 antibody-drug conjugate used as a primary treatment for patients with advanced breast cancer," said Professor Perez. "We are encouraged by the results. The study explained that T-DM1 has very good anti-tumor activity as well as much lower toxicity when evaluated side-by-side to the older "standard". T-DM1 has displayed promising activity in preclinical studies.
Reviews